Cargando…
Potential role of daratumumab in the treatment of multiple myeloma
Multiple myeloma is the second most common hematologic malignancy in the US. Treatments utilizing alkylating agents, corticosteroids, proteasome inhibitors, and immunomodulatory drugs have resulted in significant survival benefits, however, despite the advances, relapse is inevitable. Decreased dept...
Autores principales: | Khagi, Yulian, Mark, Tomer M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069139/ https://www.ncbi.nlm.nih.gov/pubmed/24971019 http://dx.doi.org/10.2147/OTT.S49480 |
Ejemplares similares
-
Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018) -
New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim, Cian, et al.
Publicado: (2017) -
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
por: Dima, Danai, et al.
Publicado: (2020) -
Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020) -
Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
por: Kalis, Joseph A.
Publicado: (2017)